Unfractionated and low-molecular-weight heparin for hypercoagulability in dogs and cats - Veterinary Medicine
  • SEARCH:
Medicine Center
DVM Veterinary Medicine Featuring Information from:

ADVERTISEMENT

Unfractionated and low-molecular-weight heparin for hypercoagulability in dogs and cats
A new type of heparin, low-molecular-weight heparin, shows promise as an effective and easier-to-use form of therapy for people prone to thromboembolism. Does the same hold true for dogs and cats?


VETERINARY MEDICINE


33. Rozanski EA, Hughes D, Scotti M, et al. The effect of heparin and fresh frozen plasma on plasma antithrombin III activity, prothrombin time and activated partial thromboplastin time in critically ill dogs. J Vet Emerg Crit Care 2001;11:15-21.

34. Plumb DC. Plumb's veterinary drug handbook. 5th ed. Ames, Iowa: Blackwell, 2005;929.

35. Diquelou A, Barbaste C, Gabaig AM, et al. Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to healthy dogs. Vet Clin Pathol 2005;34:237-242.

36. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119 (1 suppl):176S-193S.

37. Baker BA, Adelman MD, Smith PA, et al. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med 1997;157:2475-2479.

38. Mischke R, Jacobs C. The monitoring of heparin administration by screening tests in experimental dogs. Res Vet Sci 2001;70:101-108.

39. Mischke R. Heparin in vitro sensitivity of the activated partial thromboplastin time in canine plasma depends on reagent. J Vet Diagn Invest 2003;15:588-591.

40. Raschke R, Hirsh J, Guidry JR. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med 2003;138:720-723.

41. Greene CE, Meriwether E. Activated partial thromboplastin time and activated coagulation time in monitoring heparinized cats. Am J Vet Res 1982;43:1473-1477.

42. Mischke R, Grebe S, Jacobs C, et al. Amidolytic heparin activity and values for several hemostatic variables after repeated subcutaneous administration of high doses of a low molecular weight heparin in healthy dogs. Am J Vet Res 2001;62:595-598.

43. Allwood AJ, Downend AB, Simpson SA, et al. Pharmacokinetics of dalteparin and enoxaparin in healthy cats (abst). J Vet Emerg Crit Care 2005;15:S1.

44. Morris TA, Marsh JJ, Konopka R, et al. Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated heparin in venous thrombo-embolism. Thromb Res 2000;100:185-194.

45. Leadley RJ Jr, Kasiewski CJ, Bostwick JS, et al. Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin. Arterioscler Thromb Vasc Biol 1998;18:908-914.

46. Tater KC, Drellich S, Beck K. Management of femoral artery thrombosis in an immature dog. J Vet Emerg Crit Care 2005;15:52-69.

47. Goodman JS, Rozanski EA, Brown DJ, et al. The effects of low-molecular weight heparin on hematologic parameters in normal cats (abst). J Vet Intern Med 1999;13:268.

48. Smith CE, Rozanski EA, Freeman LM, et al. Use of low molecular weight heparin in cats: 57 cases (1999-2003). J Am Vet Med Assoc 2004;225:1237-1241.

49. Grebe S, Jacobs C, Kietzmann M, et al. Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs [German]. Berl Munch Tierarztl Wochenschr 2000;113:103-107.


ADVERTISEMENT

Source: VETERINARY MEDICINE,
Click here